AbbVie’s atogepant meets late-stage goal in menstrual migraine study
AbbVie said its migraine treatment atogepant, branded as Qulipta in the U.S., reduced migraine days associated with the menstrual period in a late-stage study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.